Skip to content
Ashvattha Therapeutics
Ashvattha Therapeutics
  • About Us
    • Senior Management Team
    • Board of Directors
    • Scientific Advisory Board
  • Technology
  • Pipeline
    • Overview
    • D6-B483
    • OP-801
    • D-4517.2
    • OP-101
  • News
  • Resources
  • Careers
  • Contact
Ashvattha Therapeutics
  • About Us
    • Senior Management Team
    • Board of Directors
    • Scientific Advisory Board
  • Technology
  • Pipeline
    • Overview
    • D6-B483
    • OP-801
    • D-4517.2
    • OP-101
  • News
  • Resources
  • Careers
  • Contact

Month: October 2020

Ashvattha Therapeutics Announces Formation of Scientific Advisory Board

November 12, 2020October 29, 2020 by ashvatthaadmin

Ashvattha announced the formation of a Scientific Advisory Board. The SAB will work closely with Ashvattha’s management team to select and develop highly differentiated HDTs to treat diseases with significant unmet medical need.

Categories Press Release

Ashvattha Therapeutics Selected to Present Virtual Poster at ACR Convergence 2020

November 12, 2020October 27, 2020 by ashvatthaadmin

Ashvattha announced results from a preclinical study demonstrating the successful localization of HDs to target sites of inflammation in arthritic tissues at the ACR Convergence 2020, held virtually November 5-9, 2020.

Categories Press Release

Ashvattha Therapeutics Presents Preclinical Data at the American Society of Nephrology (ASN) Virtual Kidney Week 2020

November 12, 2020October 22, 2020 by ashvatthaadmin

Ashvattha announced results from a preclinical study demonstrating targeting of HDs to renal macrophages after acute ischemia in a diabetic animal model, at the American Society of Nephrology (ASN) Kidney Week 2020, held virtually October 19-25, 2020.

Categories Press Release

Ashvattha Therapeutics Appoints Industry Veteran George G. Montgomery to its Board of Directors

November 12, 2020October 7, 2020 by ashvatthaadmin

Ashvattha Therapeutics announced the appointment of George G. Montgomery to its board of directors. Montgomery brings more than 30 years of extensive experience as an investor, entrepreneur and investment banker across diverse healthcare sectors.

Categories Press Release Leave a comment

Recent Posts

  • Ashvattha Therapeutics Announces First Patient Enrolled in a Phase 1 Study of [18F]OP-801 for Use as Imaging Agent
  • Ashvattha Therapeutics to Present at Upcoming Investor Conferences
  • Ashvattha Therapeutics to Present at Biotech Showcase 2023
  • Ashvattha Therapeutics Announces the Appointment of Steve Maricich, M.D., Ph.D. as Chief Medical Officer
  • Ashvattha Therapeutics Announces Preclinical Data on Hydroxyl Dendrimer Based PET Tracer [18F]OP-801 Presented at the 2022 World Molecular Imaging Congress

Recent Comments

    Archives

    • February 2023
    • January 2023
    • October 2022
    • September 2022
    • August 2022
    • July 2022
    • June 2022
    • May 2022
    • April 2022
    • September 2021
    • June 2021
    • May 2021
    • April 2021
    • December 2020
    • November 2020
    • October 2020
    • September 2020
    • August 2020
    • June 2020
    • May 2020

    Categories

    • In the News
    • Press Release

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org

    Howdy, this is Creativo

    We just added a brand new Off Canvas Sidebar. You can change the content you see here by going to Appearance -> Widgets -> Off Canvas Sidebar.

    Of course you can also change the design of this sidebar by going to Appearance -> Theme Options -> Off Canvas Sidebar.

    Change everything from: background color, font color, font size, sidebar headings and more.

    © Copyright 2023 Ashvattha Therapeutics.
    • Privacy Policy
    © 2023 Ashvattha Therapeutics • Built with GeneratePress